New combo therapy aims to tame thyroid eye disease

NCT ID NCT07152366

Recruiting now Disease control Sponsor: Shanghai Changzheng Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a two-step treatment for people with moderate-to-severe thyroid eye disease (TAO) that is still active. First, patients receive high-dose steroids, then a newer drug called tetuzumab (IBI311) that blocks a growth factor receptor. The goal is to reduce bulging eyes and inflammation. About 96 adults who did not respond well to steroids alone will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI311 (tetuzumab) and methylprednisolone
What this could lead to: If successful, this sequential treatment could offer a more effective option for people with thyroid eye disease who did not respond well to steroids alone.
What could go wrong: This is a small, early-phase trial with only 96 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy growth delay due to insulin-like growth factor I resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID ASSOCIATED OPHTHALMOPATHIES

Contacts and locations

Locations

Shanghai Changzheng Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.